Insulin initiation and intensification: Insights from new studies

Journal of Association of Physicians of India

Volumn 59, Issue SUPPL APRIL2011, 2011, Pages 17-22

  Kumar, Ajay ^a   Kalra, Sanjay ^b  

^a Diabetes Care and Research Centre   (India)

^b Vazeer chand Colony ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART;

ARTICLE; BLOOD; DIABETES MELLITUS; DRUG ADMINISTRATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; POSTPRANDIAL STATE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT ACCEPTANCE OF HEALTH CARE; POSTPRANDIAL PERIOD; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 80051572749     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. UK Prospective Diabetes Study (UKPDS), Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. Nathan DM, Buse JB, and Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;28:1963-72.
3. NICE Type 2 Diabetes-newer agents NICE Clinical Guideline 87 (CG 87). NICE, London, 2009.
4. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003;26:881-5.
5. Ford ES, Li C, Little RR, Mokdad A. Trends in A1C Concentrations Among U.S. Adults With Diagnosed Diabetes From 1999 to 2004. Diabetes Care 2008;31:102-104.
6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26 Suppl 3:S18-S24.
7. Peyrot M, Rubin RR, Lauritzen T et al. For the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-79.
8. Polonsky WH, Fisher L, Guzman S et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5.
9. Ligthelm RJ, Mouritzen U, Lynggaard H et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:511-9.
10. Bebakar WMW, Chow CC, Kadir KA. On behalf of the BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:724-32.
11. Christiansen JS, Vaz J, Metelkoet al. Twice daily biphasic insulin aspart improves postprandial glycemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003;5:446-54.
12. Boehm BO, Vaz JA, Brondsted L et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004;15:496-502.
13. Boehm B, Home P, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393-9.
14. Raskin P, Allen E, Hollander P, et al. for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5.
15. Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307-13.
16. Liebl A, Prager R, Binz K et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45-52.
17. Gumprecht J, Benroubi M, Borzi V et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009;63:966-72.
18. Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study Int J Clin Pract 2008;62:1013-8.
19. Strojek K, Bebakar AMW, Khutsoane DT, Pesic M, Šmahelová, Šmahelova, Thomsen HF, Kalra S. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Current Medical Research Opinion 2009;25:2887-94.
20. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Invest 2009;32:23-7.
21. Yang W, Ji QZ Hu D, Yang J, Chen L, Liu Z, Yu D, Yan L. Biphasic insulin Aspart 30 three times daily is more effective than a twicedaily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008;31:852-856.
22. Ushakova O, Sokolovskaya V, Morozova A et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia. Clinical Therapeutics 2007;29.
23. Tibaldi JT. Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycaemic control on a twice-daily regimen: A retrospective case series analysis from clinical practice. Advances in Therapies 2007;24:1348-1356.
24. Unnikrishnan AG, Tibaldi J, Hadley-brown M, Krentz A, Ligthelm R, Damci T, Gumprecht J, Gero L, Mu Y, Raz I. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract 2009;11:1571-77.
25. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf (accessed June 2009).